Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
Status:
Completed
Trial end date:
2016-02-29
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel plus
prednisone compared with placebo plus prednisone in men with metastatic, castration-resistant
prostate cancer (mCRPC) that has progressed following Docetaxel-based therapy